Pfizer Limited (PFIZER) - Total Liabilities
Based on the latest financial reports, Pfizer Limited (PFIZER) has total liabilities worth Rs-42.03 Billion INR (≈ $-454.53 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PFIZER long-term investment intensity to see how much of total assets are deployed in long-term investments.
Pfizer Limited - Total Liabilities Trend (2005–2026)
This chart illustrates how Pfizer Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see PFIZER asset base.
Pfizer Limited Competitors by Total Liabilities
The table below lists competitors of Pfizer Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AVI LTD (UNSP.ADR)/5
F:IZ60
|
Germany | €5.01 Billion |
|
IBF Financial Holdings Co Ltd
TW:2889
|
Taiwan | NT$451.77 Billion |
|
Eris Lifesciences Limited
NSE:ERIS
|
India | Rs34.70 Billion |
|
Atea ASA
OL:ATEA
|
Norway | Nkr16.70 Billion |
|
L1 Group Limited
AU:L1G
|
Australia | AU$205.86 Million |
|
Anywhere Real Estate Inc
NYSE:HOUS
|
USA | $4.22 Billion |
|
Jilin OLED Material Tech Co Ltd
SHG:688378
|
China | CN¥701.92 Million |
|
Acuren Corporation
NYSE:TIC
|
USA | $2.20 Billion |
Liability Composition Analysis (2005–2026)
This chart breaks down Pfizer Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Pfizer Limited's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | N/A | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pfizer Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pfizer Limited (2005–2026)
The table below shows the annual total liabilities of Pfizer Limited from 2005 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs7.19 Billion ≈ $77.75 Million |
+3.64% |
| 2025-03-31 | Rs6.94 Billion ≈ $75.02 Million |
+9.55% |
| 2024-03-31 | Rs6.33 Billion ≈ $68.48 Million |
-20.19% |
| 2023-03-31 | Rs7.93 Billion ≈ $85.81 Million |
-23.42% |
| 2022-03-31 | Rs10.36 Billion ≈ $112.05 Million |
+18.70% |
| 2021-03-31 | Rs8.73 Billion ≈ $94.40 Million |
-13.57% |
| 2020-03-31 | Rs10.10 Billion ≈ $109.22 Million |
+8.75% |
| 2019-03-31 | Rs9.29 Billion ≈ $100.43 Million |
-7.76% |
| 2018-03-31 | Rs10.07 Billion ≈ $108.88 Million |
+18.20% |
| 2017-03-31 | Rs8.52 Billion ≈ $92.11 Million |
+7.04% |
| 2016-03-31 | Rs7.96 Billion ≈ $86.05 Million |
+24.62% |
| 2015-03-31 | Rs6.39 Billion ≈ $69.06 Million |
+140.11% |
| 2014-03-31 | Rs2.66 Billion ≈ $28.76 Million |
-27.16% |
| 2013-03-31 | Rs3.65 Billion ≈ $39.48 Million |
+34.34% |
| 2012-03-31 | Rs2.72 Billion ≈ $29.39 Million |
+21.97% |
| 2011-03-31 | Rs2.23 Billion ≈ $24.10 Million |
+6.59% |
| 2010-03-31 | Rs2.09 Billion ≈ $22.61 Million |
+6.35% |
| 2009-03-31 | Rs1.97 Billion ≈ $21.26 Million |
-9.73% |
| 2008-03-31 | Rs2.18 Billion ≈ $23.55 Million |
+5.32% |
| 2007-03-31 | Rs2.07 Billion ≈ $22.36 Million |
+3.32% |
| 2006-03-31 | Rs2.00 Billion ≈ $21.64 Million |
+9.56% |
| 2005-03-31 | Rs1.83 Billion ≈ $19.75 Million |
-- |
About Pfizer Limited
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers therapy area and products, such as vaccines, injectables and anti-infectives, inflammation and immunology, and internal medicine for cardiovascular care, oncology, respiratory, multivitamins and multimineral, neuroscience, women's health, gastroenterolog… Read more